PRG-2311

N/A

Report date: 2024/12/25 10:14:16

Base Information

Drug NamePRG-2311
Drug Alias NamePRG-2311
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseLupus Nephritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Pregene Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Pregene Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsImmunoglobulin G4-Related DiseaseLupus Nephritis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A